Daryl C Drummond

Summary

Publications

  1. pmc A novel assay for monitoring internalization of nanocarrier coupled antibodies
    Ulrik B Nielsen
    Department of Anesthesia, University of California San Francisco, San Francisco, CA 94110, USA
    BMC Immunol 7:24. 2006
  2. pmc Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine
    Daryl C Drummond
    Hermes Biosciences, Inc, 61 Airport Blvd, Suite D, South San Francisco, CA 94080, USA
    J Pharmacol Exp Ther 328:321-30. 2009
  3. doi request reprint Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    J Pharm Sci 97:4696-740. 2008
  4. doi request reprint Development of a highly stable and targetable nanoliposomal formulation of topotecan
    Daryl C Drummond
    Hermes Biosciences, Inc, 61 Airport Boulevard, Suite D, South San Francisco, CA 94080, USA
    J Control Release 141:13-21. 2010
  5. pmc Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
    Charles O Noble
    Hermes Biosciences Inc, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 64:741-51. 2009
  6. ncbi request reprint Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    Cancer Res 66:3271-7. 2006
  7. ncbi request reprint Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
    Dmitri B Kirpotin
    Hermes Biosciences Inc, South San Francisco, CA, USA
    Cancer Res 66:6732-40. 2006
  8. ncbi request reprint Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis
    David F Nellis
    SAIC Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:221-32. 2005
  9. ncbi request reprint Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, Buck Institute for Age Research, Novato, California 94945, USA
    Clin Cancer Res 11:3392-401. 2005
  10. ncbi request reprint Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
    David F Nellis
    SAIC Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:205-20. 2005

Collaborators

  • John W Park
  • James D Marks
  • Bin Liu
  • Ulrik B Nielsen
  • Gary K Scott
  • Dmitri B Kirpotin
  • David F Nellis
  • Keelung Hong
  • Charles O Noble
  • Christopher C Benz
  • Steven L Giardina
  • Shelley C Perkins
  • Mark E Hayes
  • Zexiong Guo
  • M Refaat Shalaby
  • Yi Shao
  • Thomas F Ouellette
  • Jianwei Zhu
  • George M Janini
  • John M Roach
  • Richard Tsai
  • Timothy F Ouellette
  • Denise L Ekstrom
  • Trevor L Broadt
  • Shilpa R Shenoy
  • Robert Andersson

Detail Information

Publications11

  1. pmc A novel assay for monitoring internalization of nanocarrier coupled antibodies
    Ulrik B Nielsen
    Department of Anesthesia, University of California San Francisco, San Francisco, CA 94110, USA
    BMC Immunol 7:24. 2006
    ..We have termed this methodology "Chelated Ligand Internalization Assay", or CLIA...
  2. pmc Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine
    Daryl C Drummond
    Hermes Biosciences, Inc, 61 Airport Blvd, Suite D, South San Francisco, CA 94080, USA
    J Pharmacol Exp Ther 328:321-30. 2009
    ..8 mg VRL/kg for nanoliposomal vinorelbine. Our results demonstrate that a highly active, stable, and long-circulating liposomal vinorelbine can be prepared and warrants further study in the treatment of cancer...
  3. doi request reprint Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    J Pharm Sci 97:4696-740. 2008
    ....
  4. doi request reprint Development of a highly stable and targetable nanoliposomal formulation of topotecan
    Daryl C Drummond
    Hermes Biosciences, Inc, 61 Airport Boulevard, Suite D, South San Francisco, CA 94080, USA
    J Control Release 141:13-21. 2010
    ....
  5. pmc Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
    Charles O Noble
    Hermes Biosciences Inc, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 64:741-51. 2009
    ....
  6. ncbi request reprint Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    Cancer Res 66:3271-7. 2006
    ..This study shows that intraliposomal stabilization of CPT-11 using a polymeric or highly charged, nonpolymeric polyanionic trapping agent results in a markedly active antitumor agent with low toxicity...
  7. ncbi request reprint Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
    Dmitri B Kirpotin
    Hermes Biosciences Inc, South San Francisco, CA, USA
    Cancer Res 66:6732-40. 2006
    ..Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery...
  8. ncbi request reprint Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis
    David F Nellis
    SAIC Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:221-32. 2005
    ....
  9. ncbi request reprint Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, Buck Institute for Age Research, Novato, California 94945, USA
    Clin Cancer Res 11:3392-401. 2005
    ....
  10. ncbi request reprint Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
    David F Nellis
    SAIC Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:205-20. 2005
    ..Residual endotoxin, rProtein A, and genomic DNA, were at acceptable levels. This study successfully addressed a necessary step in the scale-up of immunoliposome-encapsulated therapeutics...
  11. ncbi request reprint Clinical development of histone deacetylase inhibitors as anticancer agents
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    Annu Rev Pharmacol Toxicol 45:495-528. 2005
    ....